LIXT: Lixte Biotechnology Holdings Stock Price

Lixte Biotechnology (LIXT) develops patented oncology inhibitors, with long-term trials ensuring stable revenue from partnerships with pharmaceutical behemoths. The price trend shown below confirms the asset's market position, with a metric of 7.17. Earnings are based on the licensing of agents that increase tumor sensitivity to radiation. High R&D costs and strict FDA regulations create a powerful barrier to entry for new participants.

lixte.com - LIXT Share Price (period 07/04/2022 - 07/06/2026)

LIXT (Lixte Biotechnology Holdings Inc.): analytical breakdowns and indicator data

- stock value and consensus price forecast:

Price Chart Lixte Biotechnology|LIXT - Price Target Chart

- market capitalization information:

Market Capitalization Lixte Biotechnology Holdings Inc.|LIXT - Company Buyout Price

- book capitalization information:

Accounting Value per Share Lixte Biotechnology|LIXT - Accounting Capitalization|Market Cap to Net Assets Ratio lixte.com|LIXT - Aggregate Business Assets

- debt and liquidity details:

Total Debt to Capital Lixte Biotechnology|LIXT - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Lixte Biotechnology Holdings|LIXT - Company Cumulative Debt|Debt to Book Capitalization Ratio Lixte Biotechnology Holdings Inc.|LIXT - Company Long-Term Indebtedness|Company Short-Term Debts Lixte Biotechnology|Quick Liquidity lixte.com

- financial results and valuation multiples details:

LIXT - Final Profit|Projected Future Earnings Lixte Biotechnology|LIXT - P/E Multiple|Future Price to Earnings Lixte Biotechnology Holdings, Inc.|LIXT - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Lixte Biotechnology Holdings Inc.|LIXT - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Lixte Biotechnology|LIXT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lixte.com|LIXT - Earnings per share growth this year|Earnings growth forecast for next year Lixte Biotechnology

Analysis of all company metrics:LIXT Lixte Biotechnology

For Lixte Biotechnology (LIXT), the asset's price trend reflects the market consensus regarding business value, capturing a real-time collective valuation of capital. This indicator measures the balance of supply and demand, which for Lixte Biotechnology (LIXT) depends directly on geopolitical risks affecting reagent logistics and the timelines of clinical trials for anti-tumor drugs, thereby determining the company's investment attractiveness vector.

Who Lixte Biotechnology competes with